First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study.
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Bile Duct Neoplasms
/ drug therapy
Deoxycytidine
/ analogs & derivatives
Female
Humans
Indazoles
Male
Middle Aged
Neoplasm Metastasis
Pyrimidines
/ pharmacology
Sulfonamides
/ pharmacology
Treatment Outcome
Gemcitabine
Biliary tract carcinoma
gemcitabine
pazopanib
phase II study
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
10
12
2019
revised:
19
12
2019
accepted:
20
12
2019
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
20
3
2020
Statut:
ppublish
Résumé
The efficacy of gemcitabine-based chemotherapy in locally advanced/metastatic biliary tract carcinoma is limited. The aim of this trial was to assess the activity of a novel gemcitabine-pazopanib combination in such patients. In this phase II, multicenter trial, patients with histologically/cytologically confirmed biliary tract carcinoma, previously untreated for advanced disease, received 1000 mg/m A total of 29 patients (median age; 69 years) were enrolled between June 2013 and March 2018. The ORR was 13.8% in the intent-to-treat and 19.1% in the per protocol population. The median progression-free and overall survival were 6.3 and 10.4 months, respectively. The low response rate precludes further testing of the combination in patients with biliary tract carcinoma.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The efficacy of gemcitabine-based chemotherapy in locally advanced/metastatic biliary tract carcinoma is limited. The aim of this trial was to assess the activity of a novel gemcitabine-pazopanib combination in such patients.
PATIENTS AND METHODS
METHODS
In this phase II, multicenter trial, patients with histologically/cytologically confirmed biliary tract carcinoma, previously untreated for advanced disease, received 1000 mg/m
RESULTS
RESULTS
A total of 29 patients (median age; 69 years) were enrolled between June 2013 and March 2018. The ORR was 13.8% in the intent-to-treat and 19.1% in the per protocol population. The median progression-free and overall survival were 6.3 and 10.4 months, respectively.
CONCLUSION
CONCLUSIONS
The low response rate precludes further testing of the combination in patients with biliary tract carcinoma.
Identifiants
pubmed: 32014937
pii: 40/2/929
doi: 10.21873/anticanres.14026
doi:
Substances chimiques
Indazoles
0
Pyrimidines
0
Sulfonamides
0
Deoxycytidine
0W860991D6
pazopanib
7RN5DR86CK
Gemcitabine
0
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
929-938Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.